Anjali Singh

All stories by Anjali Singh

MNCs look towards India for a booster dose

MNCs look towards India for a booster dose

Rediff.com1 Apr 2024

In recent months, several pharma multinational corporations (MNCs) are increasingly turning to Indian companies to expand market reach in the country's pharmaceuticals sector. Sanofi's partnerships with Dr Reddy's, Cipla, and Emcure, AstraZeneca and Mankind Pharma - teaming up for asthma medication distribution - are a few instances of this trend. This strategy allows MNCs to leverage established Indian networks and reach a wider audience. Indian companies also benefit from global brands and expertise, say analysts.

Classic Legends charts revival plan; to focus more on Asean markets

Classic Legends charts revival plan; to focus more on Asean markets

Rediff.com18 Jan 2024

Classic Legends, the owner of the Jawa and Yezdi brands, is embarking on a revival plan - from nearly doubling its dealership count in India, introducing more models, to focusing on exports to Asean markets. It recently introduced the Jawa 350 motorcycle to take on Royal Enfield. The company plans to add more models this year.

Tata Motors begins production at new Sanand plant acquired from Ford

Tata Motors begins production at new Sanand plant acquired from Ford

Rediff.com15 Jan 2024

Tata Passenger Electric Mobility (TPEM), a subsidiary of Tata Motors, on Friday announced that it has commenced production at its second factory in Sanand, Gujarat, which it had acquired from Ford India last year. This new facility will unlock an additional manufacturing capacity of 300,000 units per annum, which is scalable to 420,000 units. The new facility is spread over 460 acres and is adjacent to Tata Motors' existing passenger vehicle facility in Sanand.

Smaller electric two-wheeler players unlikely to raise prices in 2024

Smaller electric two-wheeler players unlikely to raise prices in 2024

Rediff.com4 Jan 2024

Smaller players manufacturing electric two-wheelers (E2Ws) are unlikely to raise prices of their models initially in 2024 in order to ensure volumes do not drop. The prices of E2Ws range from Rs 90,000 to Rs 1 lakh, the players being Lohia Auto, Godawari Electric, Emobi, etc. As India's E2W sector gears up to go past one million in 2024, manufacturers are likely to maintain price stability, underpinned by strategic independence from subsidies under Faster Adoption and Manufacturing of Electric (and Hybrid) Vehicles II (FAME II), localisation efforts, sustainability initiatives, and a focus on affordability.

Electric two-wheeler sales likely to breach 1 million mark in 2024

Electric two-wheeler sales likely to breach 1 million mark in 2024

Rediff.com11 Dec 2023

India's electric two-wheeler (E2W) sector is expected to cross the one million mark in 2024 fuelled by rising demand, increased production, and affordability, industry experts said, even as several original equipment makers are expanding their penetration to rural areas. Improved battery technology and innovative features are also likely to fuel growth, they said. "E2W sales will breach the 1-million mark in 2024 as the demand for electric two-wheelers is expected to continue growing due to factors such as environmental awareness, government incentives, and improvements in technology," Hyder Khan, chief executive officer (CEO), Godawari Electric Motors, said.

Luxury carmaker Lamborghini's Revuelto sold out in India, globally for 2024

Luxury carmaker Lamborghini's Revuelto sold out in India, globally for 2024

Rediff.com7 Dec 2023

Luxury carmaker Lamborghini has announced that its hybrid super sports car, Revuelto, is sold out in India and globally for 2024. The strong demand for the Revuelto is driven by a growing number of new customers, including a 20 per cent increase in first-time buyers in India. Lamborghini is also evaluating the possibility of opening new dealerships in smaller towns in eastern and southern India within the next one to two years.

'Aim to be among top three biosimilar players in world'

'Aim to be among top three biosimilar players in world'

Rediff.com30 Nov 2023

'We've got a huge track record and success in bringing several biosimilars to the market.'

Heart Disease: Why Young Women Are At Risk

Heart Disease: Why Young Women Are At Risk

Rediff.com17 Nov 2023

Practo has witnessed a 215% increase in total consultations related to cardiovascular health, with women in the age group of 25 to 34 contributing to the largest number of consultations.